Study of nerandomilast for active myositis
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system clinical trials.
This study tests a new oral medication, nerandomilast, for people with active idiopathic inflammatory myopathies (a group of rare autoimmune diseases causing muscle weakness). It aims to see if the drug can reduce disease activity safely. Participants must have moderate-to-severe symptoms and be on standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of idiopathic inflammatory myopathy (IIM) — a group of rare diseases causing muscle weakness and inflammation.
- Your disease activity must be moderate to severe, based on specific muscle strength tests and skin scores.
- You must be on a standard background treatment (e.g., steroids, methotrexate, azathioprine, or mycophenolate) with a stable dose.
- You must not have certain exclusion conditions like recent major surgery, active cancer (except treated basal cell or in situ cervical cancer), or advanced lung disease.
- If you are of childbearing potential, you must agree to use highly effective contraception during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is creating a group of patients with idiopathic inflammatory myositis (a condition where your immune system attacks your muscles) to better understand the disease and improve care. It's open to adults ages 18 to 75 who have been diagnosed using specific medical guidelines.
This trial is testing an experimental drug for safety in people with certain autoimmune diseases—like myositis, scleroderma, or Sjögren's disease—as well as in healthy volunteers. It aims to find out if the drug is safe enough to study further.
This trial tests an investigational drug called AZD5492 for people with active lupus, inflammatory myositis, or rheumatoid arthritis who haven't responded well to other treatments. It aims to see if the drug is safe and how it works in the body.
This Phase 3 trial tests how an investigational medicine (PF-06823859) works in adults with active dermatomyositis or polymyositis. It aims to improve disease control by targeting the immune system, but you must meet several safety and diagnosis requirements.
This trial tests if nerandomilast can help people with systemic sclerosis, a disease that can affect the skin and lungs. It may be an option for those with active disease and reduced lung function.
This trial tests an experimental therapy (PN-101) made from donated mitochondria, which are tiny energy-producing parts of cells. It is for adults with refractory (hard-to-treat) polymyositis or dermatomyositis. The goal is to see if PN-101 can improve muscle strength and reduce disease activity.
Hear when a new Idiopathic Inflammatory Myopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.